牛牛AI助理已提取核心訊息
Jennifer L. Taubert, EVP of Worldwide Commercialization, Innovative Medicine at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value, were not disclosed in the announcement. The action type and status of the transaction were also not provided. The report does not include information on the number of shares held by Taubert after the transaction.
Jennifer L. Taubert, EVP of Worldwide Commercialization, Innovative Medicine at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value, were not disclosed in the announcement. The action type and status of the transaction were also not provided. The report does not include information on the number of shares held by Taubert after the transaction.
強生創新醫學全球商業化執行副總裁詹妮弗·陶伯特於2024年2月15日參與了與該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和總價值。也沒有提供交易的操作類型和狀態。該報告不包括有關陶伯特在交易後持有的股票數量的信息。
強生創新醫學全球商業化執行副總裁詹妮弗·陶伯特於2024年2月15日參與了與該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和總價值。也沒有提供交易的操作類型和狀態。該報告不包括有關陶伯特在交易後持有的股票數量的信息。
有用
沒用